Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model

IntroductionDespite advances in treating high-risk neuroblastoma, 50-60% of patients still suffer relapse, necessitating new treatment options. Bispecific trifunctional antibodies (trAbs) are a promising new class of immunotherapy. TrAbs are heterodimeric IgG-like molecules that bind CD3 and a tumor...

Full description

Bibliographic Details
Main Authors: Sara Marie Ivasko, Kathleen Anders, Laura Grunewald, Michael Launspach, Anika Klaus, Silke Schwiebert, Peter Ruf, Horst Lindhofer, Holger N. Lode, Lena Andersch, Johannes H. Schulte, Angelika Eggert, Patrick Hundsdoerfer, Annette Künkele, Felix Zirngibl
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
tumor-vaccination
antibodies
immunotherapy
checkpoint inhibition
childhood cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1023206/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1023206/full

Similar Items